A tighter reimbursement environment has heightened a need for efficiency and resulted in greater specialization in biopharmaceutical R&D—and more and more pipeline cuts to focus on the best investments. Some cuts include potential therapies with promising science but lower commercial market potential or strategic relevance. These are therapies that could go on to benefit patients, but many have become deprioritized assets that are shelved. How can innovative financial and business models unlock new sources of capital to develop these assets? How are different stakeholders in the biopharmaceutical ecosystem partnering to address these challenges? What market-based solutions promise to help us fulfill the societal value of science?